Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab
Our investigation uncovered performance distinctions between lebrikizumab and dupilumab prefilled pens, which could potentially translate into patient experience, and varying levels of risk associated with intramuscular injection for the adult population and premature device removal.
Authors
- Jean-Christophe Veilleux (ORCID: https://orcid.org/0000-0002-5420-9411)
- Pavlos P. Vlachos (ORCID: https://orcid.org/0000-0002-8040-9257)
- Kevin Harrison Duffy
- Rozhin Derakhshandeh
- Javad Eshraghi (ORCID: https://orcid.org/0000-0002-1468-3805)
- Galen H. Shi
- Milad Tavakolian
Institutions
- Eli Lilly (United States) (US)
- Purdue University West Lafayette (US)
Publication Details
- Journal
- Expert Opinion on Drug Delivery
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1080/17425247.2025.2477656
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Eli Lilly and Company
- Purdue University